Last reviewed · How we verify
RENESSANS , INTERFERON ALPHA 2b, Ribavirin
This combination therapy uses interferon alpha-2b to enhance antiviral immune response and ribavirin to inhibit viral replication, targeting hepatitis C virus.
This combination therapy uses interferon alpha-2b to enhance antiviral immune response and ribavirin to inhibit viral replication, targeting hepatitis C virus. Used for Chronic hepatitis C virus infection.
At a glance
| Generic name | RENESSANS , INTERFERON ALPHA 2b, Ribavirin |
|---|---|
| Also known as | IODINE POLYMER, HEBERON, VIRON |
| Sponsor | MTI Medical Private Limited, Pakistan |
| Drug class | Antiviral combination therapy |
| Target | Hepatitis C virus NS5B RNA polymerase; interferon alpha receptor signaling |
| Modality | Biologic |
| Therapeutic area | Virology/Hepatology |
| Phase | Phase 3 |
Mechanism of action
Interferon alpha-2b activates natural killer cells and macrophages to mount an antiviral immune response against infected hepatocytes. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, reducing hepatitis C virus replication. Together, they work synergistically to clear chronic HCV infection.
Approved indications
- Chronic hepatitis C virus infection
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hemolytic anemia
- Thrombocytopenia
- Depression and neuropsychiatric effects
- Thyroid dysfunction
- Alopecia
- Nausea and gastrointestinal disturbance
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: